Cellectis Redirects Pipeline Toward In Vivo Gene Editing
Cellectis will cease internal development of lasme-cel and eti-cel, seek partners for both allogeneic CAR T assets, and concentrate internal resources on two preclinical liver-directed programs: .HEAL-101, an APOC3 TALE base editor for severe…
